Leadership

Tia Aulinskas, Ph.D., Chief Executive Officer, Lab Director and Board Member

Dr. Aulinskas co-founded Genelex in 1987 and currently serves as Chief Executive Officer and Laboratory Director. Aulinskas brings more than 30 years of experience in the field of DNA testing.

Dr. Aulinskas defines company strategy and is responsible for overall laboratory science and business operations. She has secured all laboratory accreditation and licensing including CAP, CLIA, NYDOH, AABB, ASCLD/LAB, and maintained regulatory compliance with a variety of agencies. She has directed laboratory services for multiple national, international, state and federal justice system agencies, biotechnology companies, contract clients, hospitals and individuals. Technologies implemented include genotyping, gene sequencing, probe manufacture, GCLP clinical trials services, and FDA product release testing.

Prior to co-founding Genelex, Dr. Aulinskas served as a senior research fellow in the Pathology Department and Division of Metabolism, Endocrinology and Nutrition at the University of Washington.

Dr. Aulinskas holds a doctorate and a BS, in Medical Biochemistry from the University of Cape Town, South Africa and a MS in Medical Biochemistry from the University of Stellenbosch.

 

Howard Coleman, Executive Vice President, Business Development and Board Member

Coleman co-founded Genelex in 1987 and currently serves as the business development executive.

As the former CEO, Coleman was the leading visionary behind the establishment of Genelex as a world leader in pharmacogenetic testing and medication management analytics software. Coleman is responsible for business development and is the primary liaison for governmental agencies, clients, and partners.

In addition to working at Genelex, Coleman is a Principal at Biotech Trends, LLC. He has also served as a member of the Washington State Board of Health Genetics Task Force and as faculty at the Institute for Science Training and Research. He has served as expert testimony in multiple legal cases, has written multiple publications, and is an inventor on multiple patents.

Coleman has a BS in Clinical Science and a BA in Psychology and studied at the University of Washington and Fred Hutchinson Cancer Research Center.

 

Greg Alderson, MBA, CPA, Executive Vice President and Board Member

Alderson joined Genelex in 2012 as Executive Vice President and has been a member of the Board of Directors since 1987. Alderson has extensive biotechnology and software experience with startups and Fortune 500 companies.

Alderson’s role is to apply entrepreneurial and executive level advisory skills helping guide and foster the Company’s growth. Alderson leads and manages investment opportunities, financial administration, HR, and legal.

Prior to Genelex, he served as chairman and CEO of Invizeon Corporation, a provider of advanced communications solutions. Alderson has also served in finance, operations and marketing executive management roles at BioXcelerator, Microsoft, Raima, General Information, Advanced Products & Technologies, Bristol Myers Squibb, and Genetic Systems. Alderson is an inactive CPA earned while at the Big 4 accounting firm, Deloitte.

Alderson earned his MBA from the University of Oregon. He also holds BS degrees in Microbiology and Immunology and in Food Science, both from the University of Washington.

 

Jarrod Heck, Ph.D., HCLD/TS (ABB), Associate Laboratory Director
Dr. Heck joined Genelex in 2012 and currently serves as Associate Laboratory Director. Dr. Heck has more than 15 years of experience in molecular biology and genetics.

Dr. Heck directs the clinical pharmacogenetic testing laboratory production and R&D departments. Testing implemented includes high-throughput analysis of single genes and large clinically validated gene panels, custom assay design, and biomarker development. He has secured laboratory certification as an Agena Bioscience Service Provider of MassARRAY technology, maintains regulatory compliance with a variety of agencies and facilitates CAP, CLIA, NYDOH and clinical trial audits.

Prior to Genelex, Dr. Heck served as a Postdoctoral Researcher at the Fred Hutchinson Cancer Research Center.

Dr. Heck holds a doctorate in Cell and Developmental Biology from University of California San Diego, and a BA, in Biology from the Minnesota State University Moorhead.